trinoveon’s triScan service platform, based in a PCP environment, coordinates the detection, staging and monitoring, and management of diabetic retinopathy.
Accurate
-
99% Negative Predictive Value
Economic
-
$30 per test for PCP
-
Recurring revenue with no up front capital costs.
Approved
-
FDA approved device
-
Existing CPT coding
Efficient
-
2-3 minutes per test
-
performed by medical assistant.
-
limited physician time.
Documented
-
digital reporting of results in 24-48 hour
-
easily integrates into EHR
Outcomes-Based
-
HEDIS compliant
System Elements
FDA-approved RetEval hand held scanning device.
Sensor strip applied under each eye and connect to RetEval scanner.
Medical Assistant performs the test on each eye.
triScan system transmits data to Trinoveon to be read by ophthalmologist.
triScan system generates report based on evaluation by an eye care specialist.
triScan report is transmitted back to the PCP for further management.
triScan Market Comparison
triScan Service Description
Trinoveon’s triScan service provides a test that can be done by a medical assistant in 2-3 minutes, with a 99.2% negative predictive value, generates $25-30 per test for the PCP office, provides a digital report that can be integrated to the EHR system, meets HEDIS requirements and requires no capital investment on the part of the PCP office. The test is performed by a medical assistant using a hand held ERG device (RETeval). An electrode is placed below each lower eyelid and a blinking light is shone into the eye being tested. The results are recorded on the device which is returned to its cradle where the data are sent to Trinoveon’s Reading Center. The results are reviewed by an ophthalmologist and returned in an electronic report back to the testing site. The PCP orders the test on qualified patients and bills for the procedure (see Trinoveon’s Billing Model document) using an established procedure code (CPT 92273). The software is a secure cloud-based solution, built on the Microsoft Azure platform.
Testing is performed using an untethered, hand-held RETeval ERG device (LKC Technologies, Gaithersburg, MD) to measure the retina’s response to a blinking light. Electrodes attached to the patient’s lower eyelids capture the electrical response of the retina. These data are automatically and securely sent to the Trinoveon Reading Center for interpretation and results are returned to the test site in 24-48 hours. Test interpretation evaluates three responses from each eye and compares them against a normative database, including: amplitude, implicit time and pupillometry to each of three different light intensities. A standardized report displays actual measurements as well as the test interpretation and is color coded (green/red) to indicate whether or not VTDR is present. The device is FDA approved and has been validated against the “gold-standard” of DRS 7-field, color, stereoscopic fundus imagine interpreted by the ETDRS reading protocol. The test is accurate with 99.2% NPV, 83% sensitivity and 78% specificity for detection of VTDR.